BOSTON (Reuters) - The Novartis osteoporosis drug Reclast, given once a year, reduces the risk of broken bones for three years but may spark an abnormal heart rhythm in some patients, researchers said on Wednesday."For people who either don’t want to take, or can’t take, oral drugs, this is a really good alternative that’s really effective,” said Dr. Dennis Black of the University of California San Francisco, who led the study.>>> Discuss This Story
